for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ホワドン・メディシン

000963.SZ

現在値

37.33CNY

変化

-0.86(-2.25%)

出来高

13,429,720

本日のレンジ

37.31

 - 

38.45

52週レンジ

24.55

 - 

53.94

∙ 約20分前の相場を表示しています。

適時開示

Huadong Medicine's Q3 Net Profit Down 9.9% Y/Y

Oct 26 (Reuters) - Huadong Medicine Co Ltd <000963.SZ>::SAYS Q3 NET PROFIT DOWN 9.9% Y/Y AT 595.0 MILLION YUAN.

Huadong Medicine's H1 Net Profit Down 24.9% Y/Y

Aug 9 (Reuters) - Huadong Medicine Co Ltd <000963.SZ>::SAYS H1 NET PROFIT DOWN 24.9% Y/Y AT 1.3 BILLION YUAN ($200.74 million).

Huadong Medicine's Q1 Net Profit Down, Unit Plans Asset Purchase

April 27 (Reuters) - Huadong Medicine Co Ltd <000963.SZ>::SAYS Q1 NET PROFIT DOWN 33.9% Y/Y.SAYS UNIT AGREES TO BUY 75% STAKE IN BIO-TECHNOLOGY FIRM FOR 487.5 MILLION YUAN ($75.16 million).

Huadong Medicine's 2020 Net Profit Up 0.2% Y/Y

April 20 (Reuters) - Huadong Medicine Co Ltd <000963.SZ>::SAYS 2020 NET PROFIT UP 0.2% Y/Y AT 2.8 BILLION YUAN ($430.87 million).SAYS ITS UNIT PLANS TO INVEST ABOUT 915 MILLION YUAN IN LIFE SCIENCE INDUSTRY PARK PROJECT.

Provention Bio and Huadong Announce Collaboration to Develop PRV-3279 in Greater China

Feb 17 (Reuters) - Provention Bio Inc: :PROVENTION BIO AND HUADONG ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP AND COMMERCIALIZE PRV-3279 IN GREATER CHINA.PROVENTION BIO INC - PROVENTION BIO TO RECEIVE $6 MILLION UPFRONT PAYMENT.PROVENTION BIO INC - ELIGIBLE TO RECEIVE LOW-TO-MID DOUBLE DIGIT ROYALTIES AS A PERCENTAGE NET SALES OF PRV-3279 BY HUADONG IN GREATER CHINA.PROVENTION BIO - IS ELIGIBLE TO RECEIVE ADDITIONAL MILESTONE PAYMENTS OF UP TO $172 MILLION IF CERTAIN REGULATORY AND COMMERCIAL OBJECTIVES ARE ACHIEVED.

Huadong Medicine Says Unit Agrees To Buy Spain's Medical Beauty Equipment Firm

Feb 17 (Reuters) - Huadong Medicine Co Ltd <000963.SZ>::SAYS ITS UNIT SINCLAIR PHARMA SIGNS AGREEMENT TO BUY SPAIN'S MEDICAL BEAUTY EQUIPMENT FIRM HIGH TECHNOLOGY PRODUCTS S.L.U..

Huadong Medicine's Net Profit Up Y/Y In Q3, Jan-Sept

Oct 26 (Reuters) - Huadong Medicine Co Ltd <000963.SZ>::SAYS Q3 NET PROFIT UP 7.0% Y/Y.SAYS 9-MONTH NET PROFIT UP 8.1% Y/Y.

ImmunoGen, Huadong Medicine Collaborate to Develop and Commercialize Mirvetuximab Soravtansine in Greater China

Oct 19 (Reuters) - Huadong Medicine Co Ltd <000963.SZ>::IMMUNOGEN AND HUADONG MEDICINE ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP AND COMMERCIALIZE MIRVETUXIMAB SORAVTANSINE IN GREATER CHINA.IMMUNOGEN INC - TO RECEIVE $40 MILLION UPFRONT PAYMENT AND IS ELIGIBLE TO RECEIVE UP TO $265 MILLION IN POTENTIAL MILESTONE PAYMENTS.IMMUNOGEN INC - WILL RETAIN ALL RIGHTS TO MIRVETUXIMAB IN REST OF WORLD; OUTSIDE MAINLAND CHINA, HONG KONG, MACAU, AND TAIWAN.IMMUNOGEN - HUADONG MEDICINE TO BE RESPONSIBLE FOR DEVELOPMENT, POTENTIAL REGULATORY SUBMISSIONS, COMMERCIALIZATION OF MIRVETUXIMAB IN GREATER CHINA.IMMUNOGEN INC - HUADONG MEDICINE WILL ALSO HAVE OPPORTUNITY TO PARTICIPATE IN GLOBAL CLINICAL STUDIES OF MIRVETUXIMAB CONDUCTED BY CO.

Huadong Medicine's U.K. Unit To Invest 6 Mln Euros In Swiss Firm Kylane Laboratoires

Oct 15 (Reuters) - Huadong Medicine Co Ltd <000963.SZ>::SAYS U.K. UNIT SINCLAIR PHARMA AGREES TO INVEST 6 MILLION EUROS ($7.03 million) IN SWISS FIRM KYLANE LABORATOIRES SA FOR 20%.

Huadong Medicine's H1 Net Profit Up 8.5% Y/Y

Aug 27 (Reuters) - Huadong Medicine Co Ltd <000963.SZ>::SAYS H1 NET PROFIT UP 8.5% Y/Y AT 1.7 BILLION YUAN ($247.20 million).

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up